2023 Sanofi Golden Ticket Competition!

Applications open

In partnership with Biolabs, Sanofi are pleased to announce in 2023 the launch of our Global Golden Ticket Competition that will award a promising young company with a one-year prepaid residence on BioLabs Tuft Launchpads. Two more Golden Tickets will be allocated, simultaneously, according to the same terms and themes for the BioLabs Heidelberg sites in Germany and Biolabs Hôtel Dieu, Paris, France.

The scope of this new global Golden Ticket 2023 is to promote the emergence of innovative therapeutic and technological approaches for the treatment of chronic inflammatory diseases and/or on the other hand, to modulate neuronal inflammation pathways, and more specifically:

• New immunological therapies for chronic inflammatory diseases (including enabling technologies and precision medicine approaches) e.g., mechanisms that induce tolerance and restore immune homeostasis, activation of inhibitory immune checkpoints, cytokine multi-targeting and antigen-specific therapies.
• New disease-modifying therapies targeting the neuroinflammation pathways for neurological and neurodegenerative disorders, including progressive multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s disease, Parkinson’s disease and Alzheimer’s disease.

All interested and active startups are encouraged to apply by February 10, 2023 to be eligible.  A complete application file and non-confidential presentation must be submitted in accordance with the terms and conditions detailed on the official Golden Ticket site listed below. 

Please pass this information on to parties with a potential for interest.

For further information

https://www.sanofi.com/fr/science-et-innovation/Partenariats-sanofi/golden-ticket-2023